date,title,source
Oct-26-18,Karyopharm Therapeutics Announces Management Change,GlobeNewswire
Oct-29-18,Karyopharm Therapeutics Announces Closing of Additional $22.5 Million of 3.00% Convertible Senior Notes Due 2025 Pursuant to Exercise in Full of Initial Purchasers Option,GlobeNewswire
Oct-31-18,Is Karyopharm Therapeutics Inc (NASDAQ:KPTI) Potentially Underrated?,Simply Wall St.
Nov-01-18,Karyopharm Announces Results of Clinical Studies Investigating Selinexor in Multiple Myeloma and Diffuse Large B-Cell Lymphoma to be Presented at the American Society of Hematology 2018 Annual Meeting,GlobeNewswire
Nov-01-18,"Karyopharm to Report Third Quarter 2018 Financial Results on November 8, 2018",GlobeNewswire
Nov-05-18,Karyopharm Therapeutics to Ring Nasdaq Closing Bell on November 6th,GlobeNewswire
Nov-07-18,Karyopharms Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma,GlobeNewswire
Nov-07-18,Karyopharm to Present at the Jefferies 2018 London Healthcare Conference,GlobeNewswire
Nov-08-18,"Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Lags Revenue Estimates",Zacks
Nov-08-18,Karyopharm Therapeutics: 3Q Earnings Snapshot,Associated Press
Nov-08-18,Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress,GlobeNewswire
Nov-13-18,"Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies  Future Expectations, Projections Moving into 2018",GlobeNewswire
Dec-03-18,Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at the American Society of Hematology 2018 Annual Meeting,GlobeNewswire
Dec-03-18,The 4 Healthcare Stocks To Watch On Monday,ACCESSWIRE
Dec-04-18,Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),GlobeNewswire
Dec-19-18,Karyopharm Therapeutics Inc (KPTI) Hedge Funds Are Snapping Up,Insider Monkey
Jan-02-19,Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),GlobeNewswire
Jan-02-19,How Financially Strong Is Karyopharm Therapeutics Inc. (NASDAQ:KPTI)?,Simply Wall St.
Jan-02-19,Karyopharm to Present at the 37th Annual J.P. Morgan Healthcare Conference,GlobeNewswire
Jan-08-19,Karyopharm Announces Submission of Marketing Authorization Application to the European Medicines Agency for Selinexor for the Treatment of Patients with Penta-Refractory Multiple Myeloma,GlobeNewswire
Jan-09-19,Karyopharm Files MAA for Myeloma Candidate Selinexor in EU,Zacks
Jan-11-19,Edited Transcript of KPTI earnings conference call or presentation 8-Nov-18 1:30pm GMT,Thomson Reuters StreetEvents
Feb-04-19,Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),GlobeNewswire
Feb-07-19,Karyopharm Announces FDA Advisory Committee Meeting to Review Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies,GlobeNewswire
Feb-21-19,"Research Report Identifies Johnson & Johnson, Schlumberger, Karyopharm Therapeutics, WYNDHAM DESTINATIONS, INC, ASGN, and Suburban Propane Partners with Renewed Outlook  Fundamental Analysis, Calculating Forward Movement",GlobeNewswire
Feb-21-19,"Karyopharm to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019",GlobeNewswire
Feb-22-19,Here's Why Karyopharm Therapeutics Is Getting Hammered Today,Motley Fool
Feb-22-19,Karyopharm Shares Nosedive On Tough FDA Briefing For Multiple Myeloma Drug,Benzinga
Feb-25-19,Karyopharm Strengthens Management Team with Appointment of Michael P. Mason as Chief Financial Officer,GlobeNewswire
Feb-25-19,FDA panel says Karyopharm's cancer drug shows 'significant toxicity',American City Business Journals
Feb-26-19,Karyopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma,GlobeNewswire
Feb-26-19,Karyopharm Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies,GlobeNewswire
Feb-26-19,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",Benzinga
Feb-27-19,Analysts Slash KaryoPharm Price Targets By Over 50% After Adcom Setback,Benzinga
Feb-27-19,"The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings",Benzinga
Feb-28-19,Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),GlobeNewswire
Feb-28-19,Karyopharm Therapeutics Inc (KPTI) Q4 2018 Earnings Conference Call Transcript,Motley Fool
Feb-28-19,Karyopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update,GlobeNewswire
Mar-01-19,Steven Cohen Ups Bet on Karyopharm Therapeutics,GuruFocus.com
Mar-04-19,Take a Poker Player's Approach to Playing Small Biotech Stocks,TheStreet.com
Mar-05-19,Edited Transcript of KPTI earnings conference call or presentation 28-Feb-19 1:30pm GMT,Thomson Reuters StreetEvents
Mar-07-19,Edited Transcript of KPTI earnings conference call or presentation 28-Feb-19 1:30pm GMT,Thomson Reuters StreetEvents
Mar-14-19,Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application,PR Newswire
Mar-15-19,Why Karyopharm Therapeutics Stock Is Soaring Today,Motley Fool
Mar-15-19,"The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA",Benzinga
